NZ Neurology Research Review Issue 55 - MS Focus

In this issue:

Initial DMT and conversion to secondary progressive MS
HSCT vs continued DMT in patients with RRMS
DMT and disability progression in PPMS
Inflammatory disease activity and disability accrual in progressive onset MS
Alemtuzumab vs fingolimod after natalizumab cessation in RRMS
Individual and population perspectives of MS disease burden
Dimethyl fumarate vs fingolimod or teriflunomide in MS patients
Persistence and adherence to oral DMTs
A modified premedication protocol for ocrelizumab infusion
Subcutaneous cladribine in patients who are ineligible for oral DMTs

Please login below to download this issue (PDF)

Subscribe